Active surveillance for prostate cancer: Patient selection and management

Current Oncology

Volumn 17, Issue SUPPL. 2, 2010, Pages

  Klotz, Laurence ^a  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

Active surveillance; Cancer screening; Overdiagnosis; PSA

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; STEROID 5ALPHA REDUCTASE INHIBITOR;

AGE; ARTICLE; CANCER EPIDEMIOLOGY; CANCER GRADING; CANCER GROWTH; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; CANCER SURGERY; CLINICAL TRIAL; DIAGNOSTIC ERROR; DRUG COST; EARLY DIAGNOSIS; FOLLOW UP; HEALTH CARE AVAILABILITY; HEALTH CARE UTILIZATION; HISTOPATHOLOGY; HUMAN; INTERMETHOD COMPARISON; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT EDUCATION; PATIENT IDENTIFICATION; PATIENT MONITORING; PATIENT SAFETY; PATIENT SELECTION; PROSTATE BIOPSY; PROSTATE CANCER; QUALITY OF LIFE; REASSURANCE; RISK FACTOR; THERAPY DELAY; WATCHFUL WAITING;

EID: 78149443864     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.v17i0.713     Document Type: Article

References (31)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49.
2. Welch HG, Black WC. Overdiagnosis in cancer. J Natl Cancer Inst 2010;102:605-13.
3. Schröder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009;360:1320-8.
4. Roobol M, Kerkhof M, Schroder F, et al. Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (erspc). Eur Urol 2009;56:584-91.
5. Sakr WA, Haas GP, Cassin BF, Pontes JE, Crissman JD. The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J Urol 1993;150:379-85.
6. van As NJ, Parker CC. Active surveillance with selective radical treatment for localized prostate cancer. Cancer J 2007;13:289-94.
7. Carter HB, Kettermann A, Warlick C, et al. Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience. J Urol 2007;178:2359-65.
8. Khatami A, Aus G, Damber JE, Lilja H, Lodding P, Hugosson J. psa doubling time predicts the outcome after active surveillance in screening-detected prostate cancer: results from the European randomized study of screening for prostate cancer, Sweden section. Int J Cancer 2007;120:170-4.
9. Roemeling S, Roobol MJ, de Vries SH, et al. Active surveillance for prostate cancers detected in three subsequent rounds of a screening trial: characteristics, psa doubling times, and outcome. Eur Urol 2007;51:1244-50.
10. Soloway MS, Soloway CT, Williams S, Ayyathurai R, Kava B, Manoharan M. Active surveillance; a reasonable management alternative for patients with prostate cancer: the Miami experience. BJU Int 2008;101:165-9.
11. van den Bergh RC, Roemeling S, Roobol MJ, et al. Outcomes of men with screen-detected prostate cancer eligible for active surveillance who were managed expectantly. Eur Urol 2009;55:1-8.
12. Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 2010;28:126-31
13. Parker C. Active surveillance: towards a new paradigm in the management of early prostate cancer. Lancet Oncol 2004;5:101-6.
14. van den Bergh RC, Vasarainen H, van der Poel HG, et al. Short-term outcomes of the prospective multicentre "Prostate Cancer Research International: Active Surveillance" study. BJU Int 2010;105:956-62.
15. Shappley WV 3rd, Kenfield SA, Kasperzyk JL, et al. Prospective study of determinants and outcomes of deferred treatment or watchful waiting among men with prostate cancer in a nationwide cohort. J Clin Oncol 2009;27:4980-5.
16. Zhang L, Loblaw A, Klotz L. Modeling prostate specific antigen kinetics in patients on active surveillance. J Urol 2006;176:1392-7.
17. Carter HB, Kettermann A, Warlick C, et al. Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience. J Urol 2007;178:2359-64.
18. D'Amico AV, Chen MH, Roehl KA, Catalona WJ. Preoperative psa velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 2004;351:125-35.
19. Scattoni V, Zlotta A, Montironi R, Schulman C, Rigatti P, Montorsi F. Extended and saturation prostatic biopsy in the diagnosis and characterisation of prostate cancer: a critical analysis of the literature. Eur Urol 2007;52:1309-22.
20. Engelbrecht MR, Puech P, Colin P, Akin O, Lemaître L, Villers A. Multimodality magnetic resonance imaging of prostate cancer. J Endourol 2010;24:677-84.
21. Lawrentschuk N, Haider MA, Daljeet N, et al. "Prostatic evasive anterior tumours": the role of magnetic resonance imaging. BJU Int 2009;105:1231-6.
22. Holmberg L, Bill-Axelson A, Helgesen F, et al. on behalf of the Scandinavian Prostatic Cancer Group Study Number 4. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med 2002;347:781-9.
23. Steineck G, Helgesen F, Adolfsson J, et al. Quality of life after radical prostatectomy or watchful waiting. N Engl J Med 2002;347:790-6.
24. Burnet KL, Parker C, Dearnaley D, Brewin CR, Watson M. Does active surveillance for men with localized prostate cancer carry psychological morbidity? BJU Int 2007;100:540-3.
25. van den Bergh R, Essink-Bot ML, Roobol MJ, Schröder FH, Bangma CH, Steyerberg EW. Do anxiety and distress increase during active surveillance for low risk prostate cancer? J Urol 2010;183:1786-91.
26. Graif T, Loeb S, Roehl KA, et al. Under diagnosis and over diagnosis of prostate cancer. J Urol 2007;178:88-92.
27. Hou AH, Sullivan KF, Crawford ED. Targeted focal therapy for prostate cancer: a review. Curr Opin Urol 2009;19:283-9.
28. Zheng SL, Sun J, Wiklund F, et al. Cumulative association of five genetic variants with prostate cancer. N Engl J Med 2008;358:910-19.
29. Nam R, Saskin R, Lee Y, Liu Y, et al. Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy. J Urol 2010;183:963-8.
30. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349:215-24.
31. Andriole G, Bostwick D, Brawley O, et al. Further analyses from the reduce prostate cancer risk reduction trial [abstract LBA1]. Presented at the American Urological Association meeting; Chicago, IL; April 25-30, 2009. [Available online at: www.aua2010.org/Attendees/lba09/lba1.pdf; cited June 18, 2010]